A SYSTEMATIC REVIEW ON CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA

Abstract

Objective: A systematic review of literature addressing the efficacy and safety of caplacizumab for patients with acquired thrombotic thrombocytopenic purpura (aTTP) was done. Methods: The literature search for 5 years (2017–2021) was conducted using particular search terms in databases/search engines (PubMed, Cochrane), and articles were screened based on inclusion and exclusion criteria. A total of 394 peoples were involved in the selected studies. Results: With caplacizumab, the median time to normalization of the platelet count was faster than with a placebo. In comparison to those who received a placebo, patients who received caplacizumab required fewer plasma exchanges and spent less time in the hospital. Mucocutaneous bleeding was reported by 65% of participants receiving caplacizumab and 48% of patients receiving a placebo as the most frequent side effect. Three patients died in the placebo group. After the trial period, one patient died due to cerebral ischemia in the caplacizumab group. Conclusion: Caplacizumab was efficacious and well tolerated in patients with aTTP who experienced a diseases exacerbation.